Dose escalation • 25%

Safety assessment • 25%

Efficacy assessment • 25%

Trial termination • 25%

Hold Lifted • 33%

Hold Extended • 33%

New Restrictions • 34%

Trial Resumed • 33%

Trial Terminated • 33%

Trial Modified • 34%

Yes • 50%

No • 50%

Respiratory drug • 25%

Immunology drug • 25%

Vaccine • 25%

Other • 25%

Phase 2 • 25%

Phase 3 • 25%

Trial termination • 25%

No announcement • 25%

FDA Approval • 25%

EMA Approval • 25%

Additional Phase 3 Trials • 25%

Other • 25%

Phase 2 Completion • 25%

Partnership/Acquisition • 25%

FDA Approval • 25%

Other • 25%

Initiation of Phase 1 clinical trials • 25%

Publication of preclinical study results • 25%

Securing additional funding • 25%

Partnership with a major pharmaceutical company • 25%

Yes • 50%

No • 50%

Lung Cancer • 25%

Breast Cancer • 25%

Colorectal Cancer • 25%

Other Cancer Type • 25%

Successful Phase I trial • 25%

FDA Fast Track designation • 25%

Publication of promising preclinical results • 25%

No major milestone achieved • 25%